Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.53 USD
0.00 (0.00%)
Updated May 13, 2024 04:00 PM ET
After-Market: $3.53 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum C VGM
Price, Consensus and EPS Surprise
RLMD 3.53 0.00(0.00%)
Will RLMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RLMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RLMD
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
RLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Other News for RLMD
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial Footing
Relmada Therapeutics GAAP EPS of -$0.72 beats by $0.15
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...